{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T02:06:53Z","timestamp":1794708413469,"version":"4.9.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Female sex has been suggested as a risk modifier for stroke in patients with atrial fibrillation (AF) with comorbid prevalent stroke risk factors. Management has evolved over time towards a holistic approach that may have diminished any sex difference in AF-related stroke. In a nationwide cohort of AF\u00a0patients free from oral anticoagulant treatment, we examine the time trends in stroke risk overall and in relation to risk differences between male and female patients. Here we show that among 158,982 patients with AF (median age 78 years (IQR: 71 to 85); 52% female) the 1-year thromboembolic risk was highest between 1997\u20132000 with a risk of 5.6% and lowest between 2013\u20132016 with a risk of 3.8%, declining over the last two decades. The excess stroke risk for female vs male patients has also been declining, with risk-score adjusted relative risk estimates suggesting limited sex-difference in recent years.<\/jats:p>","DOI":"10.1038\/s41467-024-51193-0","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T19:02:25Z","timestamp":1723057345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Risk of stroke in male and female patients with atrial fibrillation in a nationwide cohort"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2922-6970","authenticated-orcid":false,"given":"Peter Br\u00f8nnum","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5537-6767","authenticated-orcid":false,"given":"Rasmus Froberg","family":"Br\u00f8ndum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Krogh","family":"N\u00f8hr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8096-0236","authenticated-orcid":false,"given":"Thure Filskov","family":"Overvad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"key":"51193_CR1","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks, G. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 42, 373\u2013498 (2021).","journal-title":"Eur. Heart J."},{"key":"51193_CR2","doi-asserted-by":"publisher","unstructured":"Wang, Y. et al. Expert Reviewers. 2024 Chinese Expert Consensus Guidelines on the Diagnosis and Treatment of Atrial Fibrillation in the Elderly, Endorsed by Geriatric Society of Chinese Medical Association (Cardiovascular Group) and Chinese Society of Geriatric Health Medicine (Cardiovascular branch): Executive Summary. Thromb. Haemost. https:\/\/doi.org\/10.1055\/a-2325-5923 (2024).","DOI":"10.1055\/a-2325-5923"},{"key":"51193_CR3","doi-asserted-by":"publisher","first-page":"020","DOI":"10.1055\/s-0041-1739411","volume":"122","author":"T-F Chao","year":"2022","unstructured":"Chao, T.-F. et al. 2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary. Thromb. Haemost. 122, 020\u2013047 (2022).","journal-title":"Thromb. Haemost."},{"key":"51193_CR4","doi-asserted-by":"publisher","unstructured":"Pilcher, S. M., Alamneh, E. A., Chalmers, L. & Bereznicki, L. R. The Tasmanian Atrial Fibrillation Study (TAFS): differences in stroke prevention according to sex. Ann. Pharmacother. https:\/\/doi.org\/10.1177\/1060028020904969 (2020).","DOI":"10.1177\/1060028020904969"},{"key":"51193_CR5","doi-asserted-by":"crossref","unstructured":"Corica B, Lobban T, True Hills M, Proietti M, Romiti GF. Sex as a Risk Factor for Atrial Fibrillation-Related Stroke. Thromb. Haemost. 124, 281\u2013285 (2024).","DOI":"10.1055\/s-0043-1776394"},{"key":"51193_CR6","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1161\/CIRCULATIONAHA.117.029081","volume":"137","author":"PB Nielsen","year":"2018","unstructured":"Nielsen, P. B., Skj\u00f8th, F., Overvad, T. F., Larsen, T. B. & Lip, G. Y. H. Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA2DS2-VA score rather than CHA2DS2-VASc? Circulation 137, 832\u2013840 (2018).","journal-title":"Circulation"},{"key":"51193_CR7","doi-asserted-by":"publisher","first-page":"e2342258","DOI":"10.1001\/jamanetworkopen.2023.42258","volume":"6","author":"B Corica","year":"2023","unstructured":"Corica, B., Romiti, G. F. & Proietti, M. Anticoagulation in patients with atrial fibrillation who are frail\u2014toward better care. JAMA Netw. Open 6, e2342258 (2023).","journal-title":"JAMA Netw. Open"},{"key":"51193_CR8","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","volume":"14","author":"GYH Lip","year":"2017","unstructured":"Lip, G. Y. H. The ABC pathway: an integrated approach to improve AF management. Nat. Rev. Cardiol. 14, 627\u2013628 (2017).","journal-title":"Nat. Rev. Cardiol."},{"key":"51193_CR9","doi-asserted-by":"publisher","first-page":"h7013","DOI":"10.1136\/bmj.h7013","volume":"532","author":"CA Emdin","year":"2016","unstructured":"Emdin, C. A. et al. Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies. BMJ 532, h7013 (2016).","journal-title":"BMJ"},{"key":"51193_CR10","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1001\/jamacardio.2016.0529","volume":"1","author":"JP Piccini","year":"2016","unstructured":"Piccini, J. P. et al. Differences in clinical and functional outcomes of atrial fibrillation in women and men: two-year results from the ORBIT-AF registry. JAMA Cardiol. 1, 282\u2013291 (2016).","journal-title":"JAMA Cardiol."},{"key":"51193_CR11","doi-asserted-by":"publisher","first-page":"e3522","DOI":"10.1136\/bmj.e3522","volume":"344","author":"L Friberg","year":"2012","unstructured":"Friberg, L., Benson, L., Rosenqvist, M. & Lip, G. Y. H. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ 344, e3522\u2013e3522 (2012).","journal-title":"BMJ"},{"key":"51193_CR12","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1001\/jama.2012.3490","volume":"307","author":"M Avgil Tsadok","year":"2012","unstructured":"Avgil Tsadok, M. et al. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. JAMA 307, 1952\u20131958 (2012).","journal-title":"JAMA"},{"key":"51193_CR13","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1093\/qjmed\/hcu054","volume":"107","author":"AJ Wagstaff","year":"2014","unstructured":"Wagstaff, A. J., Overvad, T. F., Lip, G. Y. & Lane, D. A. Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. QJM 107, 955\u2013967 (2014).","journal-title":"QJM"},{"key":"51193_CR14","doi-asserted-by":"publisher","first-page":"100596","DOI":"10.1016\/j.lanepe.2023.100596","volume":"28","author":"M Ding","year":"2023","unstructured":"Ding, M., Ebeling, M., Ziegler, L., Wennberg, A. & Modig, K. Time trends in atrial fibrillation-related stroke during 2001\u20132020 in Sweden: a nationwide, observational study. Lancet Reg. Health Eur. 28, 100596 (2023).","journal-title":"Lancet Reg. Health Eur."},{"key":"51193_CR15","doi-asserted-by":"publisher","first-page":"101757","DOI":"10.1016\/j.eclinm.2022.101757","volume":"55","author":"GF Romiti","year":"2023","unstructured":"Romiti, G. F. et al. Adherence to the Atrial Fibrillation Better Care (ABC) pathway and the risk of major outcomes in patients with atrial fibrillation: A post-hoc analysis from the prospective GLORIA-AF Registry. EClinicalMedicine 55, 101757 (2023).","journal-title":"EClinicalMedicine"},{"key":"51193_CR16","doi-asserted-by":"publisher","first-page":"m2724","DOI":"10.1136\/bmj.m2724","volume":"370","author":"N Vinter","year":"2020","unstructured":"Vinter, N. et al. Trends in excess mortality associated with atrial fibrillation over 45 years (Framingham Heart Study): community based cohort study. BMJ 370, m2724 (2020).","journal-title":"BMJ"},{"key":"51193_CR17","doi-asserted-by":"crossref","unstructured":"The Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 69, 546\u2013554 (2007).","DOI":"10.1212\/01.wnl.0000267275.68538.8d"},{"key":"51193_CR18","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1016\/j.amjcard.2019.02.056","volume":"123","author":"M Avgil Tsadok","year":"2019","unstructured":"Avgil Tsadok, M. et al. Comparison of stroke risk stratification scores for atrial fibrillation. Am. J. Cardiol. 123, 1828\u20131834 (2019).","journal-title":"Am. J. Cardiol."},{"key":"51193_CR19","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/j.hlc.2018.08.012","volume":"28","author":"TF Overvad","year":"2019","unstructured":"Overvad, T. F., Potpara, T. S. & Nielsen, P. B. Stroke risk stratification: CHA2DS2-VA or CHA2DS2-VASc? Hear. Lung Circ. 28, e14\u2013e15 (2019).","journal-title":"Hear. Lung Circ."},{"key":"51193_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/eurheartj\/ehad508","volume":"45","author":"H Buhari","year":"2024","unstructured":"Buhari, H. et al. Stroke risk in women with atrial fibrillation. Eur. Heart J. 45, 104\u2013113 (2024).","journal-title":"Eur. Heart J."},{"key":"51193_CR21","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/1060028020904969","volume":"54","author":"SM Pilcher","year":"2020","unstructured":"Pilcher, S. M., Alamneh, E. A., Chalmers, L. & Bereznicki, L. R. The Tasmanian Atrial Fibrillation Study (TAFS): differences in stroke prevention according to sex. Ann. Pharmacother. 54, 837\u2013845 (2020).","journal-title":"Ann. Pharmacother."},{"key":"51193_CR22","doi-asserted-by":"publisher","unstructured":"Brieger, D. et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the diagnosis and management of atrial fibrillation 2018. Heart Lung Circul. https:\/\/doi.org\/10.1016\/j.hlc.2018.06.1043 (2018).","DOI":"10.1016\/j.hlc.2018.06.1043"},{"key":"51193_CR23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11739-019-02134-z","volume":"15","author":"I Marzona","year":"2020","unstructured":"Marzona, I. et al. Sex-related differences in prevalence, treatment and outcomes in patients with atrial fibrillation. Intern. Emerg. Med. 15, 231\u2013240 (2020).","journal-title":"Intern. Emerg. Med."},{"key":"51193_CR24","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1161\/STROKEAHA.116.015900","volume":"48","author":"C Lang","year":"2017","unstructured":"Lang, C. et al. Do women with atrial fibrillation experience more severe strokes? Results from the Austrian stroke unit registry. Stroke 48, 778\u2013780 (2017).","journal-title":"Stroke"},{"key":"51193_CR25","doi-asserted-by":"crossref","unstructured":"Teppo K, Lip GYH, Airaksinen K, et al. Comparing CHA2DS2-VA and CHA2DS2-VASc scores for stroke risk stratification in patients with atrial fibrillation: a temporal trends analysis from the retrospective Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) cohort. The Lancet Regional Health - Europe 43, 100967 (2024).","DOI":"10.1016\/j.lanepe.2024.100967"},{"key":"51193_CR26","doi-asserted-by":"publisher","first-page":"6770","DOI":"10.3390\/jcm12216770","volume":"12","author":"SY Choi","year":"2023","unstructured":"Choi, S. Y. et al. RETRACTED: Choi et al. Validation of the CHA2DS2-VA Score (Excluding Female Sex) in Nonvalvular Atrial Fibrillation Patients: A Nationwide Population-Based Study. J. Clin. Med. 2022, 11, 1823. J. Clin. Med. 12, 6770 (2023).","journal-title":"J. Clin. Med."},{"key":"51193_CR27","doi-asserted-by":"crossref","unstructured":"Lip, G. Y. H. et al. Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal. Europace 25, euad226 (2023).","DOI":"10.1093\/europace\/euad226"},{"key":"51193_CR28","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1093\/eurheartj\/ehl015","volume":"27","author":"R Nieuwlaat","year":"2006","unstructured":"Nieuwlaat, R. et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur. Heart J. 27, 3018\u20133026 (2006).","journal-title":"Eur. Heart J."},{"key":"51193_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1177\/1403494811401482","volume":"39","author":"E Lynge","year":"2011","unstructured":"Lynge, E., Sandegaard, J. & Rebolj, M. The Danish National Patient Register. Scand. J. Public Health 39, 30\u201333 (2011).","journal-title":"Scand. J. Public Health"},{"key":"51193_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1403494810394717","volume":"39","author":"HW Kildemoes","year":"2011","unstructured":"Kildemoes, H. W., S\u00f8rensen, H. T. & Hallas, J. The Danish National Prescription Registry. Scand. J. Public Health 39, 38\u201341 (2011).","journal-title":"Scand. J. Public Health"},{"key":"51193_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/1403494810387965","volume":"39","author":"CBC Pedersen","year":"2011","unstructured":"Pedersen, C. B. C. The Danish civil registration system. Scand. J. Public Health 39, 22\u201325 (2011).","journal-title":"Scand. J. Public Health"},{"key":"51193_CR32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2147\/CLEP.S245060","volume":"12","author":"JFH Arendt","year":"2020","unstructured":"Arendt, J. F. H. et al. Existing data sources in clinical epidemiology: laboratory information system databases in Denmark. Clin. Epidemiol. 12, 469\u2013475 (2020).","journal-title":"Clin. Epidemiol."},{"key":"51193_CR33","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/europace\/eut395","volume":"16","author":"GJ Wynn","year":"2014","unstructured":"Wynn, G. J. et al. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace 16, 965\u2013972 (2014).","journal-title":"Europace"},{"key":"51193_CR34","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/CLEP.S91125","volume":"7","author":"M Schmidt","year":"2015","unstructured":"Schmidt, M. et al. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin. Epidemiol. 7, 449\u2013490 (2015).","journal-title":"Clin. Epidemiol."},{"key":"51193_CR35","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jacc.2017.10.085","volume":"71","author":"T-F Chao","year":"2018","unstructured":"Chao, T.-F. et al. Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation. J. Am. Coll. Cardiol. 71, 122\u2013132 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"51193_CR36","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1177\/1536867X1001000308","volume":"10","author":"ET Parner","year":"2010","unstructured":"Parner, E. T. & Andersen, P. K. Regression analysis of censored data using Pseudo-observations. Stata J. Promot. Commun. Stat. Stata 10, 408\u2013422 (2010).","journal-title":"Stata J. Promot. Commun. Stat. Stata"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51193-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51193-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51193-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T19:03:24Z","timestamp":1723057404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-51193-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51193"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-51193-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"5 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.Y.H.L.: Consultant and speaker for BMS\/Pfizer, Boehringer Ingelheim and Daiichi-Sankyo. No fees are received personally. P.B.N.: Consultant fees from Boehringer Ingelheim, grants and consultant fees from Daiichi-Sankoy, grants from BMS\/Pfizer, and grants and consultant fees from Bayer outside the submitted work. Other authors: None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6728"}}